Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1)

Antiviral Therapy

Volumn 9, Issue 6, 2004, Pages 993-1002

  Cano Soldado, Pedro ^a   Larráyoz, Ignacio M ^b   Molina Arcas, Míriam ^a   Casado, F Javier ^a   Martinez Picado, Javier ^c   Lostao, M Pilar ^b   Pastor Anglada, Marçal ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CYTIDINE; DOXIFLURIDINE; GEMCITABINE; HYDROXYL GROUP; LAMIVUDINE; NUCLEOSIDE TRANSPORTER; PYRIMIDINE NUCLEOSIDE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SLC28A1 PROTEIN; STAVUDINE; THYMIDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TRANSPORT; GENETIC TRANSFECTION; NONHUMAN; NUCLEOSIDE TRANSPORT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRANSPORT KINETICS; VOLTAGE CLAMP; XENOPUS LAEVIS;

ANIMALS; ANTI-HIV AGENTS; CHO CELLS; CRICETINAE; DRUG INTERACTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NUCLEOSIDE TRANSPORT PROTEINS; OOCYTES; PATCH-CLAMP TECHNIQUES; REVERSE TRANSCRIPTASE INHIBITORS; TRANSFECTION; XENOPUS LAEVIS;

EID: 11144260100     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Baldwin SA, Mackey JR, Cass CE & Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Molecular Medicine Today 1999; 5:216-224.
2. Gray JH, Owen RP & Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Archiv: European Journal of Physiology 2004; 447:728-734.
3. Huang QQ, Yao SY, Ritzel MW, Paterson AR, Cass CE & Young JD. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. Journal of Biological Chemistry 1994; 269:17757-17760.
4. Pastor-Anglada M, Felipe A & Casado FJ. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends in Pharmacological Sciences 1998; 19:424-430.
5. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR & Cass CE. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Reseach 1998; 58:4349-4357.
6. Lostao MP, Mata JF, Larrayoz IM, Inzillo SM, Casado FJ & Pastor-Anglada M. Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Letters 2000; 481:137-140.
7. Mata JF, Garcia-Manteiga JM, Lostao MP, Fernandez-Veledo S, Guillen-Gomez E, Larrayoz IM, Lloberas J, Casado FJ & Pastor-Anglada M. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Molecular Pharmacology 2001; 59:1542-1548.
8. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A & Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clinical Cancer Research 2003; 9:5000-5008.
9. Valdes R, Ortega MA, Casado FJ, Felipe A, Gil A, Sanchez-Pozo A & Pastor-Anglada M. Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology 2000; 119:1623-1630.
10. Mangravite LM, Lipschutz JH, Mostov KE & Giacomini KM. Localization of GFP-tagged concentrative nucleoside transporters in a renal polarized epithelial cell line. American Journal of Physiology. Renal Physiology 2001; 280:F879-F885.
11. Casado FJ, Lostao MP, Aymerich I, Larrayoz IM, Duflot S, Rodriguez-Mulero S & Pastor-Anglada M. Nucleoside transporters in absorptive epithelia. Journal of Physiology & Biochemistry 2002; 58:207-216.
12. Lai Y, Bakken AH & Unadkat JD. Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies. Journal of Biological Chemistry 2002; 277:37711-37717.
13. Mangravite LM, Badagnani I & Giacomini KM. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. European Journal of Pharmacology 2003; 479:269-281.
14. Duflot S, Calvo M, Casado FJ, Enrich C & Pastor-Anglada M. Concentrative nucleoside transporter (rCNT1) is targeted to the apical membrane through the hepatic transcytotic pathway. Experimental Cell Research 2002; 281:77-85.
15. Pastor-Anglada M, Casado FJ, Valdes R, Mata J, Garcia-Manteiga J & Molina M. Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Molecular Membrane Biology 2001; 18:81-85.
16. Soler C, Valdes R, Garcia-Manteiga J, Xaus J, Comalada M, Casado FJ, Modolell M, Nicholson B, MacLeod C, Felipe A, Celada A & Pastor-Anglada M. Lipopolysaccharide-induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms. Journal of Biological Chemistry 2001; 276:30043-30049.
17. Soler C, Garcia-Manteiga J, Valdes R, Xaus J, Comalada M, Casado FJ, Pastor-Anglada M, Celada A & Felipe A. Macrophages require different nucleoside transport systems for proliferation and activation. FASEB Journal 2001; 15:1979-1988.
18. Stevenson M. HIV-1 pathogenesis. Nature Medicine 2003; 9:853-860.
19. del Santo B, Valdes R, Mata J, Felipe A, Casado FJ & Pastor-Anglada M. Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cells. Hepatology 1998; 28:1504-1511.
20. Valdes R, Casado FJ & Pastor-Anglada M. Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. Biochemical & Biophysical Research Communications 2002; 296:575-579.
21. Wallace LJ, Candlish D & De Koning HP. Different substrate recognition motifs of human and trypanosome nucleobase transporters. Selective uptake of purine antimetabolites. Journal of Biological Chemistry 2002; 277:26149-26156.
22. Larrayoz IM, Casado FJ, Pastor-Anglada M & Lostao MP. Electrophysiological characterization of the human Na(+)/nucleoside cotranspotter 1 (hCNT1) and role of adenosine on hCNT1 function. Journal of Biological Chemistry 2004; 279:8999-9007.
23. Dresser MJ, Gerstin KM, Gray AT, Loo DD & Giacomini KM. Electrophysiological analysis of the substrate selectivity of a sodium-coupled nucleoside transporter (rCNT1) expressed in Xenopus laevis oocvtes. Drug Metabolism & Disposition 2000; 28:1135-1140.
24. Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD & Cass CE. Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Molecular Pharmacology 2003; 64:1512-1520.
25. De Koning HP, Al-Salabi MI, Cohen AM, Coombs GH & Wastling JM. Identification and characterisation of high affinity nucleoside and nucleobase transporters in Toxoplasma gondii. International Journal for Parasitology 2003; 33:821-831.
26. Mangravite LM, Xiao G & Giacomini KM. Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells. American Journal of Physiology. Renal Physiology 2003; 284:F902-F910.
27. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA & Young JD. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Molecular Membrane Biology 2001; 18:161-167.
28. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Journal of Biological Chemistry 2001; 276:2914-2927.
29. Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y & Endou H. Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. Journal of Pharmacology & Experimental Therapeutics 2000; 294:844-849.
30. Chen R & Nelson JA. Role of organic cation transporters in the renal secretion of nucleosides. Biochemical Pharmacology 2000; 60:215-219.
31. Morita N, Kusuhara H, Sekine T, Endou H & Sugiyama Y. Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. Journal of Pharmacology & Experimental Therapeutics 2001; 298:1179-1184.
32. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T & Endou H. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. Journal of Pharmacology & Experimental Therapeutics 2002; 300:918-924.
33. Hasegawa M, Kusuhara H, Endou H & Sugiyama Y. Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. Journal of Pharmacology & Experimental Therapeutics 2003; 305:1087-1097.
34. Koepsell H & Endou H. The SLC22 drug transporter family. Pflugers Archiv. European Journal of Physiology 2004; 447:666-676.
35. + gradient. American Journal of Physiology. Renal Physiology 2003; 284:F763-F769.
36. Dresser MJ, Leabman MK & Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. Journal of Pharmaceutical Sciences 2001; 90:397-421.